Mississippi Center for Advanced Medicine

Madison, Mississippi 39110-6115

0 studies enrolling now · 19 studies all time

What they study most

Adeno-Associated Virus (AAV), Adrenal Insufficiency, Arrythmia, Asthma in Children, Attention Deficit Hyperactivity Disorder, Blood Coagulation Disorder, Blood Coagulation Disorders, Inherited, Bronchopulmonary Dysplasia, Coagulation Disorder, Coagulation Protein Disorders, Coronavirus Infection (COVID-19), Down Syndrome

Studies at this site

• Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) — Recruiting now
• Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively — Recruiting now
• A Phase 2/3 Study in Adult and Adolescent Participants With SCD — Recruiting now
• A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight — Running, not enrolling
• A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP) — Running, not enrolling
• A Study to Evaluate the Efficacy and Safety of Factor IX Gene Therapy With PF-06838435 in Adult Males With Moderately Severe to Severe Hemophilia B — Running, not enrolling
• Long-term Safety and Efficacy Study and Dose-Escalation Substudy of PF 06838435 in Individuals With Hemophilia B — Running, not enrolling
• A Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab as Adjunct Treatment in Prevention of Vaso-Occlusive Episodes (VOE) in Sickle Cell Disease (SCD) — Completed
• GBT021601-022: A Study of GBT021601 in Participants With Sickle Cell Disease (SCD) — Stopped early
• Oxbryta® Product Registry An Observational Study Designed to Evaluate the Effect of Oxbryta in Individuals With SCD — Stopped early
• A Study to Evaluate Prospective Efficacy and Safety Data of Current FIX Prophylaxis Replacement Therapy in Adult Hemophilia B Subjects (FIX:C≤2%) or Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Subjects (FVIII:C≤1%) — Completed
• DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) Pathway — Completed
• A Gene Transfer Study for Hemophilia A — Completed
• Long-Term Safety and Efficacy of Spark-Sponsored Gene Therapies in Males With Hemophilia A — Running, not enrolling
• A Gene Therapy Study of BMN 331 in Subjects With Hereditary Angioedema — Running, not enrolling
• Dose-finding Study of SPK-8016 Gene Therapy in Patients With Hemophilia A to Support Evaluation in Individuals With FVIII Inhibitors — Completed
• Lead-in Study to Collect Prospective Efficacy and Safety Data of Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Participants — Completed
• A Safety, Tolerability, and Pharmacokinetics Study of a Single Intravenous Injection of Recombinant Coagulation Factor VIII Fc - Von Willebrand Factor - XTEN Fusion Protein (rFVIIIFc-VWF-XTEN) (BIVV001) in Previously Treated Adults With Severe Hemophilia A (EXTEN-A) — Completed
• A Gene Therapy Study for Hemophilia B — Completed